Article
Medicine, General & Internal
Barham K. Abu Dayyeh, Daniel B. Maselli, Babusai Rapaka, Thomas Lavin, Mark Noar, Hisham Hussan, Christopher G. Chapman, Violeta Popov, Pichamol Jirapinyo, Andres Acosta, Eric J. Vargas, Andrew C. Storm, Fateh Bazerbachi, Marvin Ryou, Matthew French, Sabrena Noria, Daniel Molina, Christopher C. Thompson
Summary: The study on obese adults showed that using an adjustable intragastric balloon combined with lifestyle intervention can significantly reduce weight and maintain it for 6 months. Adjusting the balloon volume allows for personalized therapy, maximizing weight loss and tolerance.
Article
Surgery
Danielle Abbitt, Adom Netsanet, Alexandra Kovar, Kevin Choy, Teresa S. Jones, Benjamin Cassell, Hazem Hammad, Robert Matthew Reveille, Krzysztof J. Wikiel, Edward L. Jones
Summary: Intragastric balloon placement is safe and effective in achieving preoperative weight loss for patients undergoing elective joint replacement or hernia repair. More than 75% of patients achieved optimal weight and underwent surgery after the use of intragastric balloon.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Article
Gastroenterology & Hepatology
Olufemi Aoko, Tobias Maharaj, Fiona Boland, Danny Cheriyan, John Ryan
Summary: Through a comprehensive analysis of 19 studies, it is found that intragastric balloons have a certain impact on NAFLD parameters, including NAFLD activity score (NAS), ALT, liver volume, and liver steatosis. In addition, non-liver-related outcomes such as body weight, BMI, glycated hemoglobin, and HOMA-IR are also significantly improved.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Fateh Bazerbachi, Eric J. Vargas, Monika Rizk, Daniel B. Maselli, Taofic Mounajjed, Sudhakar K. Venkatesh, Kymberly D. Watt, John D. Port, Rita Basu, Andres Acosta, Ibrahim Hanouneh, Naveen Gara, Meera Shah, Manpreet Mundi, Matthew Clark, Karen Grothe, Andrew C. Storm, Michael J. Levy, Barham K. Abu Dayyeh
Summary: In a prospective study, the intragastric balloon (IGB) facilitated significant metabolic and histologic improvements in patients with NASH. The treatment appears to be safe and effective for NASH management when combined with a prescribed diet and exercise program.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Surgery
Saurabh Chandan, Babu P. Mohan, Shahab R. Khan, Antonio Facciorusso, Daryl Ramai, Lena L. Kassab, Neil Bhogal, Ravishankar Asokkumar, Gortrand Lopez-Nava, Stephanie McDonough, Douglas G. Adler
Summary: The systematic review and meta-analysis showed that intragastric balloon (IGB) therapy is effective in improving steatosis, NAFLD activity score (NAS), and HOMA-IR score in patients with NAFLD. Additionally, a significant reduction in liver volume was observed in patients undergoing IGB placement.
Review
Gastroenterology & Hepatology
Daryl Ramai, Jameel Singh, Babu P. Mohan, Ogenetega Madedor, Olivia W. Brooks, Mohamed Barakat, Andrew Ofosu, Shahab R. Khan, Saurabh Chandan, Banreet Dhindsa, Amaninder Dhaliwal, Antonio Facciorusso, Stephanie McDonough, Douglas G. Adler
Summary: The Elipse intragastric balloon is a safe, effective, and well-tolerated device for weight loss and obesity, with the ability to effectively reduce body weight and improve metabolic profile. The study indicates that the Elipse balloon is associated with fewer adverse events compared to other IGBs.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2021)
Article
Health Care Sciences & Services
Mohammed A. Bawahab, Khaled S. Abbas, Walid M. Abd El Maksoud, Reem S. Abdelgadir, Khaled Altumairi, Awadh R. Alqahtani, Hassan A. Alzahrani, Muneer Jan Bhat
Summary: This retrospective study aimed to determine the factors affecting weight reduction after intragastric balloon (IGB) insertion. The study found that IGB therapy is a safe and effective option for obesity management, with factors such as age, initial weight and body mass index, duration of IGB insertion, and parity significantly affecting weight loss outcomes. Further larger prospective studies are needed to confirm these results.
Article
Endocrinology & Metabolism
Stefan P. Gazdzinski, Aleksandra Mojkowska, Agata Gazdzinska, Maria Gorycka, Piotr Zielinski, Ryszard Pacho
Summary: The study found that treatment with IGB can lead to brain structural improvements in patients with morbid obesity, and changes in myo-inositol ratios are related to increases in brain volume.
OBESITY RESEARCH & CLINICAL PRACTICE
(2021)
Article
Gastroenterology & Hepatology
Federico Salomone, Walter Currenti, Giovanni Magri, Ivo Boskoski, Shira Zelber-Sagi, Fabio Galvano
Summary: This study evaluated the impact of intragastric balloon (IGB) placement in NAFLD patients with advanced fibrosis, showing that IGB can lead to weight loss and reduction in liver stiffness and FIB-4 levels within 6 months. Gastroesophageal reflux symptoms were common, but no severe adverse events were observed.
LIVER INTERNATIONAL
(2021)
Article
Surgery
Rahil H. H. Shah, Shyam Vedantam, Shria Kumar, Sunil Amin, Michelle Pearlman, Sean Bhalla
Summary: By analyzing 17 studies involving 1198 patients, it was found that intragastric balloon (IGB) therapy for 6 months can significantly reduce fasting blood glucose, systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein, and triglyceride levels. This suggests that IGB therapy can not only promote weight loss but also improve insulin resistance, blood pressure, and dyslipidemia.
Article
Gastroenterology & Hepatology
Eric Swei, Aymen Almuhaidb, Shelby Sullivan, Abdullah Al-Shahrani, Felicia R. D'Souza, Osama Altayar, Suzanne Bell, Rachel Maday, Mihir S. Wagh, Dan Mullady, Michael Bennett, Dayna Early, Vladimir Kushnir
Summary: This study compared the efficacy, tolerance, and safety of the gas-filled intragastric balloon (IGB) system and the fluid-filled IGB system in clinical practice. The results showed that there was no difference in weight loss effectiveness between the two systems, but the fluid-filled IGB system had more serious adverse events and poorer tolerability compared to the gas-filled IGB system.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2023)
Article
Surgery
David Lew, Chelsea Thampy, Abdelkader Hawasli
Summary: The study found that weight loss achieved from Dual Intragastric Balloon (DIGB) therapy was not maintained after balloon removal on average. Most patients were dissatisfied and would not choose DIGB for weight loss again.
AMERICAN JOURNAL OF SURGERY
(2021)
Article
Multidisciplinary Sciences
Shweta Mital, Hai V. Nguyen
Summary: The study found that using procedure-less intragastric balloon (PIGB) as a bridge to bariatric surgery is more cost-effective than undergoing bariatric surgery alone, as it helps achieve a lower post-operative BMI. Additionally, compared to no treatment, using PIGB alone also presents a certain level of cost-effectiveness.
Article
Surgery
Mohammad H. Jamal, Nour Al-Kanawati, Rawan ElAbd, Mohannad Al-Haddad, Talal AlKhadher, Fatima Hamshari, Shehab Akrouf
Summary: The study investigated the safety and efficacy of the new balloon Orbera365 in weight loss treatment over a one-year period. The results showed that while Orbera365 is effective in weight loss, there are also risks of complications associated with its use.
Article
Surgery
Mariano Palermo, C. Federico Davrieux
Summary: This study analyzed the first experience of implementing a swallowable balloon for the treatment of obesity in Argentina. The results showed that the treatment was effective, safe, and well tolerated, with no severe adverse effects.
JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES
(2023)